Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PARSIDOL vs CYCLOBENZAPRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Treatment of parkinsonism (including drug-induced extrapyramidal reactions) in patients intolerant to or unresponsive to other anticholinergic agents
Treatment of muscle spasm associated with acute, painful musculoskeletal conditions (FDA approved),Adjunct to rest and physical therapy for relief of muscle spasm (FDA approved)
Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Terminal elimination half-life: 12-24 hours (prolonged in elderly and renal impairment, requiring dose adjustment).
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Primarily hepatic via cytochrome P450 enzymes (CYP2D6), with metabolites excreted in urine and bile. The exact metabolic pathway is not fully elucidated.
Hepatic metabolism primarily via CYP3A4, CYP1A2, and CYP2D6; also undergoes N-demethylation and glucuronidation. Active metabolites include norcyclobenzaprine.
Renal: 60-70% as unchanged drug; biliary/fecal: 15-20% as metabolites; minor respiratory elimination.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
90-95% bound to albumin and alpha-1-acid glycoprotein.
~93% bound to albumin and alpha-1-acid glycoprotein.
Vd: 7-10 L/kg (high, indicating extensive tissue distribution with accumulation in CNS and adipose tissue).
~5 L/kg (range 3–7 L/kg). Clinical meaning: extensive tissue distribution, including central nervous system.
Oral: 40-50% due to first-pass metabolism; IM: ~75%.
Oral: 33–55% due to first-pass metabolism; lower for immediate-release compared to extended-release (same extent but slower absorption).
GFR 30-89 m L/min: Reduce dose by 50%; GFR <30 m L/min: Avoid use or extend dosing interval to 12-24 hours.
No specific dosing adjustment recommended; use caution in severe renal impairment due to potential accumulation.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Contraindicated due to risk of toxicity (minimal data). Use with caution in mild to moderate impairment; consider lower starting dose.
Not recommended for children under 12 years; for age ≥12 years: 0.5-1 mg/kg/day divided every 6-12 hours, max 20 mg/day.
Not recommended for children under 15 years; safety and efficacy not established. For adolescents ≥15 years: same as adult dosing.
Initial dose 1.25-2.5 mg once or twice daily; titrate slowly. Avoid if possible due to anticholinergic side effects.
Start with 5 mg once daily; increase slowly to a maximum of 10 mg three times daily over 2 weeks. Increased sensitivity; monitor for anticholinergic effects and sedation.
None.
None
May cause drowsiness, dizziness, or blurred vision; patients should not drive or operate machinery until effects are known.,Caution in patients with glaucoma, prostatic hypertrophy, urinary retention, or gastrointestinal obstruction.,May exacerbate tardive dyskinesia or other movement disorders.,Abrupt withdrawal may precipitate parkinsonian crisis.,Use with caution in elderly patients due to increased sensitivity to anticholinergic effects.,Hepatic or renal impairment may require dose adjustment.
Serotonin syndrome risk, especially with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs),Sedation and impairment of motor skills; caution with driving or operating machinery,Anticholinergic effects (e.g., urinary retention, angle-closure glaucoma, constipation),Cardiovascular effects: tachycardia, QT prolongation, arrhythmias (especially in elderly or with pre-existing heart disease),Hepatic impairment: use with caution; reduced clearance in mild impairment, avoid in severe impairment,Withdrawal symptoms after abrupt discontinuation: dysphoria, anxiety, insomnia,Elderly patients: increased risk of falls, confusion, anticholinergic toxicity
Hypersensitivity to ethopropazine or any phenothiazine,Narrow-angle glaucoma,Obstructive uropathy (e.g., prostatic hypertrophy),Pyloric or duodenal obstruction,Myasthenia gravis
Hypersensitivity to cyclobenzaprine or any component of the formulation,Concomitant use or within 14 days of MAO inhibitors (hypertensive crisis risk),Acute recovery phase after myocardial infarction,Arrhythmias, heart block, or conduction disturbances,Hyperthyroidism,Severe hepatic impairment
No significant food interactions. Avoid excessive alcohol consumption due to additive central nervous system depression.
Alcohol should be avoided due to additive CNS depression. Grapefruit juice may increase cyclobenzaprine levels (though data is limited, caution is advised). High-fat meals may delay absorption but not clinically significant. No specific dietary restrictions are required.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No evidence of fetal harm; risk of extrapyramidal symptoms (EPS) in neonates if used near term.
Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. First trimester: Limited human data, but no structural anomalies reported. Second trimester: No specific adverse effects documented. Third trimester: Potential for neonatal withdrawal symptoms (e.g., jitteriness, respiratory depression) if used near term.
No data on M/P ratio. Excretion into breast milk likely low due to high protein binding (90-95%). Consider risk of EPS in the infant; use with caution.
Cyclobenzaprine is excreted into breast milk in low amounts; the M/P ratio is unknown. Due to its anticholinergic effects, there is potential for adverse effects in the nursing infant (e.g., sedation, constipation). The American Academy of Pediatrics considers it compatible with breastfeeding, but caution is advised; alternatives may be preferred.
No specific dose adjustments required; however, increased plasma volume may reduce drug levels. Monitor clinical response and adjust dose if needed. Avoid use in first trimester if possible.
No specific dose adjustments are recommended during pregnancy. Pharmacokinetic parameters (e.g., clearance) are not significantly altered by pregnancy. Use the lowest effective dose for the shortest duration due to lack of safety data.
Parsidol (ethopropazine) is an anticholinergic agent used primarily for Parkinsonism and extrapyramidal symptoms. Monitor for central anticholinergic effects (delirium, hallucinations) especially in elderly. Taper slowly to avoid withdrawal. Not first-line due to sedative properties.
Cyclobenzaprine is structurally related to tricyclic antidepressants and shares similar anticholinergic and sedative properties. Onset of action for muscle relaxation is typically 1 hour, but maximal effect may take several days. Avoid use in patients with hyperthyroidism, cardiac disease, or those on MAOIs. Not recommended for use longer than 2-3 weeks due to lack of evidence for chronic use. Caution in elderly due to anticholinergic effects and fall risk.
May cause drowsiness or blurred vision; avoid driving until you know how it affects you.,Avoid alcohol as it can increase sedation.,Report any confusion, hallucinations, or difficulty urinating to your doctor.,Do not stop abruptly; follow your doctor's instructions to taper off.,Stay hydrated but note it may reduce sweating, increasing risk of heatstroke.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol or use other CNS depressants (e.g., benzodiazepines, opioids) while taking this medication, as it may increase sedation.,Take this medication exactly as prescribed, usually 3 times a day. Do not take more or less than directed.,This medication is intended for short-term use (up to 2-3 weeks) for muscle spasm. Do not use it for longer without consulting your doctor.,If you experience dry mouth, try sucking on sugar-free candy or ice chips. If you have difficulty urinating or vision changes, contact your doctor.,Do not stop taking this medication abruptly without consulting your doctor, although withdrawal is uncommon with short-term use.
No interactions on record
"The combination of cyclobenzaprine and carbinoxamine results in additive central nervous system depression due to their shared anticholinergic and sedative properties. This can lead to excessive sedation, impaired cognitive and motor function, and increased risk of falls or accidents. Severe cases may result in respiratory depression, especially in elderly patients or those with preexisting conditions."
"Cyclobenzaprine, a centrally acting muscle relaxant with tricyclic antidepressant (TCA)-like structure, and Dezocine, an opioid partial agonist analgesic with mu-opioid receptor activity, both depress the central nervous system (CNS) and have additive serotonergic effects. Concomitant use increases the risk of excessive CNS depression, manifesting as sedation, respiratory depression, and impaired psychomotor function, as well as potential serotonin syndrome due to combined serotonergic activity. Clinically, patients may experience profound drowsiness, confusion, respiratory compromise, and in severe cases, coma or death from respiratory failure."
"Lumacaftor, a potent inducer of cytochrome P450 (CYP) 3A4, significantly reduces the systemic exposure of cyclobenzaprine, a CYP3A4 substrate. This results in decreased plasma concentrations of cyclobenzaprine, potentially leading to reduced therapeutic efficacy for muscle spasm relief. Patients may require dose adjustments or alternative therapies to maintain clinical benefit."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PARSIDOL vs CYCLOBENZAPRINE HYDROCHLORIDE, answered by our medical review team.
PARSIDOL is a Skeletal Muscle Relaxant that works by Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.. CYCLOBENZAPRINE HYDROCHLORIDE is a Skeletal Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PARSIDOL and CYCLOBENZAPRINE HYDROCHLORIDE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PARSIDOL is: Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.. The standard adult dose of CYCLOBENZAPRINE HYDROCHLORIDE is: Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PARSIDOL and CYCLOBENZAPRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PARSIDOL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No evidence of fetal harm; risk of extrapyrami. CYCLOBENZAPRINE HYDROCHLORIDE is classified as Category A/B. Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.